CEL-SCI Corporation
CVM
Rank in Stocks
#25809
CEL-SCI Corporation (CVM) focuses on the research and development of... CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Share Price
$1.35
Last synced: 2026-11-09
Market Cap
$23.75M
Change (1 day)
-6.90%
Change (1 year)
-80.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade CEL-SCI Corporation (CVM)
Category
Healthcare
Operating Margin for CEL-SCI Corporation (CVM)
Operating Margin as of November 2026 TTM: 0.00%
According to CEL-SCI Corporation's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for CEL-SCI Corporation from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -5,188.28% | 18.89% |
| 2019 | -4,364.11% | 24.00% |
| 2018 | -3,519.47% | -88.62% |
| 2017 | -30,916.13% | 244.88% |
| 2016 | -8,964.31% | 71.82% |
| 2015 | -5,217.18% | -99.95% |
| 2014 | -10,443,433.96% | -16.12% |
| 2013 | -12,450,120.63% | 183,739.97% |
| 2012 | -6,772.26% | 260.03% |
| 2011 | -1,881.04% | -84.46% |
| 2010 | -12,107.14% | -19.33% |
| 2009 | -15,008.12% | -92.01% |
| 2008 | -187,804.40% | 1,045.50% |
| 2007 | -16,395.02% | 284.52% |
| 2006 | -4,263.77% | 182.03% |
| 2005 | -1,511.82% | 19.30% |
| 2004 | -1,267.27% | -1.21% |
| 2003 | -1,282.84% | -21.56% |
| 2002 | -1,635.54% | -44.20% |
| 2001 | -2,931.14% | 38.32% |
| 2000 | -2,119.08% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about CEL-SCI Corporation's operating margin
What was CEL-SCI Corporation's operating margin in 2025?
In 2025, CEL-SCI Corporation's operating margin was 0.00%, compared with 0.00% in 2024.
How has CEL-SCI Corporation's operating margin changed since 2020?
From 2020 to 2025, CEL-SCI Corporation's operating margin was highest in 2025 (0.00%) and lowest in 2020 (-5,188.28%).
How does CEL-SCI Corporation's operating margin compare with similar companies?
CEL-SCI Corporation's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.